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The combination of short-acting dihydroartemisinin and long-acting piperaquine (DP) is
among the first-line therapies for the treatment of uncomplicated Plasmodium falciparum
malaria. Population pharmacokinetic models of piperaquine (PQ) based on data from acute
treatment of young children can be used to predict exposure profiles of piperaquine under
different DP chemoprevention regimens. The purpose of our study was to make such pre-
dictions in young children.
Methods
Based on a prior population pharmacokinetic model of PQ in young Ugandan children, we
simulated capillary plasma concentration-time profiles (including their variability) of candi-
date chemoprevention regimens for a reference population of 1–2 year olds weighing at
least 11 kg. Candidate regimens that were tested included monthly administration of stan-
dard therapeutic doses, bimonthly dosing, and weekly dosing (with and without a loading
dose).
Results
Once daily doses of 320 mg for three days (960 mg total) at the beginning of each month
are predicted to achieve an average steady-state trough capillary piperaquine concentration
of 35 ng/mL, with 60% achieving a level of 30 ng/mL or higher. In contrast, weekly dosing of
320 mg (i.e., 33% higher amount per month) is predicted to approximately double the aver-
age steady-state trough concentration, increase the percent of children predicted to achieve
30 ng/mL or higher (94%), while at the same time lowering peak concentrations. Exposure
at steady-state, reached at approximately 3 months of multiple dosing, is expected to be
approximately 2-fold higher than exposure following initial dosing, due to accumulation. A
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loading dose improves early exposure, thereby reducing the risk of breakthrough infections
at the initiation of chemoprevention.
Conclusions
Once weekly chemoprevention of DP predicts favourable exposures with respect to both
trough and peak concentrations. These predictions need to be verified, as well as safety
evaluated, in field-based clinical studies of young children. Simulations based on prior
knowledge provide a systematic information-driven approach to evaluate candidate DP
chemopreventive regimens for future trial designs.
Introduction
Over the past decade, the landscape of malaria therapy has undergone a dramatic shift to the
use of artemisinin-based combination therapies (ACTs) as first-line treatment for uncompli-
cated Plasmodium falciparummalaria [1]. These drug regimens have proven to be highly effec-
tive, and their use has previously been restricted to the treatment of acute disease. While the
short-acting artemisinin “backbone” rapidly reduces parasite burden, a longer-acting partner
drug, such as piperaquine (PQ), serves to eliminate residual parasites and reduce the probabil-
ity that resistance will emerge. Dihydroartemisinin-piperaquine (DHA-PQ; DP), the newest of
the World Health Organizations (WHO) first-line recommended regimens for treatment, has
been highly efficacious, although recent studies have already demonstrated the emergence of
resistance to DHA and PQ in Southeast Asia [1–5].
Concurrent to these developments, DP is under evaluation for chemoprevention, in large
part due to the long half-life of PQ (approximately 1 month) [6–8]. Chemopreventive
approaches include intermittent preventive treatment (IPT), which uses “therapeutic” doses of
antimalarials given at predefined intervals and is directed at the high-risk groups of pregnant
women and infants in endemic areas [1]. Seasonal malaria chemoprevention (SMC) uses treat-
ment doses during specific high-risk months [8, 9]. Chemopreventive DP regimens have been
highly effective in children from Senegal [10], The Gambia [11], Burkina Faso[8], and Uganda
[7, 12, 13]. In a recent study of monthly chemoprevention in Tororo, Uganda, DP was superior
to alternative regimens (monthly sulfadoxine-pyrimethamine (SP) or daily trimethoprim-sul-
famethoxazole (TS)) [7, 13]. It is likely that higher resistance to the alternative regimens (SP or
TS) and the extended half-life of PQ were key determinants of DP’s superior efficacy.
Table 1. DP weight-based dosing guidelines.
Body Weight (kg) Recommended Dose (mg)
Former WHODP dosing regimen[22] Revised WHO2015 DP dosing regimen[1]
5 to 7 160
8 to 10 160 240
11 to 14 240 320
15 to 16 320 320
17 to 19 320 480
20 to 23 400 480
24 480 480
doi:10.1371/journal.pone.0154623.t001
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Optimizing the exposure to DP in the preventive setting by improving adherence and fine-
tuning the dosing regimen is likewise critical to ensuring its optimal efficacy, limiting its toxic-
ity, and prolonging its useful therapeutic life span [14]. Despite the excellent chemopreventive
efficacy of DP, adherence to monthly regimens of three consecutive daily doses of DP is chal-
lenging. Evidence from Senegal suggests that only 70% of all children received all 3 doses of
IPT each month of the 3-month treatment [10]. A study from Uganda reported that 52% of
PQ levels were below the limit of detection at the time malaria was diagnosed and PQ levels did
not correlate with time since last reported dose, both of which suggest poor adherence [13]. In
the setting of treatment, infants and young children have been shown to have lower DP expo-
sure which correlates with higher rates of recurrent infection than in older children and adults
[6, 15–17]. As a result of these and other pharmacokinetic (PK) and pharmacodynamic (PD)
studies of DP, recent 2015 WHO guidelines have recommended higher treatment doses of DP,
particularly in young children (Table 1) [1].
Significantly less attention has been focused on characterizing the exposure of DP with che-
moprevention. A study in Thai adults found that monthly DP was superior to bimonthly DP
for preventing uncomplicated malaria, likely due to a decline in PQ concentrations below a
protective threshold in the second month after dosing with the latter [18]. In this study, all sub-
jects with recurrent infection had trough venous plasma concentrations below 32 ng/mL. Simi-
larly, in a Ugandan monthly DP chemoprevention study in children, PQ exposure was strongly
predictive of protective efficacy [19]. On the other hand, a recent adult DP chemoprevention
study was halted due to concerns of QT prolongation associated with high peak PQ levels [20].
Assuming that a threshold concentration for effective preventive treatment exists, and that
PK determines the profile of systemic exposure, we hypothesized that known (prior) PK can
inform dosing of PQ-containing preventive regimens to optimize efficacy and limit toxicity. In
the study reported herein, we use a population PK model from a study of DP treatment in chil-
dren ages 6 months to 2 years in the high transmission area of Tororo, Uganda [6, 15] to simu-
late PQ concentration-time profiles with various DP preventive regimens.
Materials and Methods
Pharmacokinetic Model
Data were simulated based on a previously published model for the same population [6].
Briefly, the model was derived from a population PK study of 107 children 6 months to 2 years
of age from Tororo, Uganda, that was part of a larger clinical trial comparing the efficacy of
artemether-lumefantrine to DP for treatment of uncomplicated malaria [15, 21]. DP was
administered to children with food as a single treatment of 3 daily doses (20/160 mg DHA/PQ
per dose for patients weighing 5.1–10.4 kg, and 30/240 mg DHA/PQ per dose for those weigh-
ing 10.5–14.5 kg), according to 2010 World Health Organization Malaria Treatment Guide-
lines (Table 1) [22]. Capillary plasma samples for PK analysis were obtained during each
episode (with an average 2 episodes per child). Population PK models were constructed using
mixed effects modeling with the program NONMEM1 [23]. The final model was a three-com-
partment open model with first-order absorption, unconditional allometric scaling of each of
the three clearance and three volume of distribution parameters and a statistically significant
age effect on CL/F [6]. The final model for CL/F was as follows:







in which WTi is the body weight (kg) and AGEi the age (month) of the ith child. Weight was
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centered at 8.36 kg (the approximately median value of a 1 year-old in this population), and
age at 12 months for ease of interpretation.
Population PK Simulations
Simulations of data sets with 2000 hypothetical 1–2 year olds weighing 11 kg were generated
(referred to as the reference population). This population was selected, rather than simulate all
ages/weight groups, for purposes of efficiency. Assuming that the ratio of doses in the preven-
tive setting is similar to that in the acute setting, one can infer the required dose in non-simu-
lated groups from that of the simulated reference group. To mimic the original data, a linear
regression model was used to simulate weight [6]. This model included variability and a corre-
lation (r2) between age and weight of 0.21. An alternate method (not available at the time the
simulation study began), would be to use published regional weight-for-age charts [24]. The
first 2000 individuals with the combined age and weight that met the prescribed criterion were
included in the capillary plasma concentration simulations. The program NONMEM1, Ver-
sion 7.3 (ICON, Dublin, Ireland) [23] generated the predictions and the program R (version
2.15.0) was used to create the plots. Administered doses and PK were assumed to remain con-
stant within an individual and we assumed the absence of any drug interaction as well as the
absence of a disease (active malaria infection) effect. Considering that the drug may be used
continuously in some settings, PK descriptors of particular interest included PQ capillary
plasma trough concentration during the first 5 months (the time during which concentrations
are increasing) and at steady-state (after 12 months of dosing). In addition, we summarized
peak concentrations at steady-state and after a loading dose, overall concentration-time profile
at steady-state, and overall concentration-time profile during the first month with and without
a loading dose. For purposes of this study, a loading dose was defined as the standard three
consecutive daily dose regimen.
The regimen that served as a point of reference was 240 mg (standard dose for acute treat-
ment in those weighing 10.5 to 14.5 kg per WHO 2010 guidelines) given daily for 3 days at the
beginning of each month, as this schedule has been most studied in treatment and prevention
trials [22]. An increased dosing regimen of 320 mg (new recommended dose for acute treat-
ment in those weighing 11–16 kg per 2015 WHO guidelines) [1] was also simulated, as well as
increasing the total dose level further by 25%, varying the dosing frequency [monthly,
bimonthly (twice monthly), and weekly] and administering a loading dose.
Given that precise target PQ concentrations in different endemic and demographic settings
are still being evaluated in the setting of treatment, and with minimal data available in chemo-
prevention settings, we chose to focus on putative target capillary plasma trough (prior to each
dose) steady-state concentrations of 10, 20 and 30 ng/mL, allowing one to compare exposure
levels between different approaches. A trough PQ venous plasma level of 32 ng/mL was found
to be associated with the risk of breakthrough malaria in Thai adults given DP chemopreven-
tion [18]. Additionally, a day 7 capillary plasma level of 57 ng/mL (equating to a venous plasma
level of 30 ng/mL) was selected as a target-of-interest, based on data from treatment studies
showing that this threshold is predictive of the risk of recurrent malaria [17, 25, 26].
Results
Effects of changing DP dose level on piperaquine exposure
Fig 1 and Table 2 show the effects on PQ exposure seen with various changes in the DP regi-
men, including an increase in dose, while maintaining a consistent frequency. An increase in
monthly PQ dose from 240 mg to 320 mg (given once daily x 3) was associated with a predicted
PQ trough steady-state capillary plasma concentration that increased from 27 to 35 ng/mL.
Simulations of Piperaquine Chemoprevention Dosing Regimens
PLOS ONE | DOI:10.1371/journal.pone.0154623 May 16, 2016 4 / 13
With an increase to 400 mg per dose, predicted PQ trough steady-state capillary plasma con-
centrations increased to 44 ng/mL. While all doses tested are predicted to achieve trough capil-
lary plasma concentrations of 10 ng/mL in 93% or more individuals, differentiation among
doses widens with target trough levels of 20 ng/mL and 30 ng/mL. Additionally, as compared
with the 240 mg dose, a 50% increase in the number of individuals predicted to achieve day 7
levels of above 57 ng/mL is expected with a 400 mg dose.
Current chemoprevention trials have studied regimens of three consecutive doses given
daily each month, though adherence to this regimen is suboptimal [10, 13]. An alternative
approach that may improve adherence is to either reduce the number of consecutive doses
(two doses daily each month), or increase the frequency of dosing to either twice monthly/
every two weeks or weekly (below). Reducing the number of consecutive doses to 2 doses while
increasing the amount in each dose (to 320 mg or 400 mg) leads to predicted exposure that is
comparable to the reference regimen (Fig 1 and Table 2).
Fig 1. Predicted capillary plasma PQ concentration versus time for various chemoprevention regimens of DP
in 1–2 year olds weighing 11 kg. For each combination of dose (240 mg, 320 mg, or 400 mg) and schedule (3
times once monthly, once weekly, 2 times once monthly or once every 15 days), there is a set of 3 panels, with the left
panel (box plots) showing trough concentrations at the end of the first 5 months, the middle panel the steady-state PK
profile during the first 3 days after the first dose of the month, and the right panel the steady-state PK profile during
days 3–30 (or days 3–28 for weekly dosing) relative to a first dose of the month. For the PK profiles, the middle line
represents the population predictions, the grey shaded area the 50% prediction interval and the outer bounds the 90%
prediction interval. The grey horizontal lines indicate capillary plasma concentrations of 10, 20, and 30 ng/mL (for
putative trough targets), and a capillary plasma level of 57 ng/mL (for a putative day 7 target).
doi:10.1371/journal.pone.0154623.g001
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Effects of changing the dosing frequency on piperaquine exposure
Increasing the dosing frequency to twice monthly also leads to steady-state trough concentra-
tions comparable to those of the reference. Compared to the reference regimen, 320 mg twice
monthly achieves similar steady-state trough concentrations, while 400 mg twice monthly
leads to a 36% increase in steady-state trough concentrations and a 46% increase in predicted
percent of individuals with troughs above 30 ng/mL. A further increase in the dosing frequency
to single weekly doses results in additional improvement in PQ trough exposure. Compared to
the reference regimen, weekly 240 mg, 320 mg, and 400 mg doses increase the steady-state
trough concentration by 2-fold, 2.8-fold, and 3.5-fold, respectively. In addition, even with a 240
mg dose,>99% and>84% of individuals are predicted to have trough concentrations above 10
ng/mL and 30 ng/mL, respectively.
Effects of dosing changes on peak plasma piperaquine concentration
While no clear threshold peak concentration has been linked with toxicity, a recent trial
reported that PQ exhibited a concentration-dependent effect on QT prolongation. Adults
whose PQ venous plasma peaks were in the range of approximately 500 to 1000 ng/mL had a
higher risk of cardiotoxicity [27]. Given this potential relationship, capillary plasma peaks
were evaluated in our simulation study (Fig 1 and Table 2). While more frequent dosing
results in higher troughs, mean predicted peak PQ capillary plasma concentration is substan-
tially lower, going from 544 ng/mL to 340 ng/mL with monthly (x 3) versus once weekly dos-
ing of 320 mg, respectively, despite higher total monthly doses with the later. Similar
reductions in predicted peak concentrations are noted with the weekly 240 mg and 400 mg
regimens. Peaks with the bimonthly regimens are likewise lower, in part due to the lower
total monthly doses.
Table 2. Predictions related to trough and peak capillary plasma concentration of PQ at steady-state with various chemoprevention regimens of
DP in 1–2 year olds weighing 11 kg.






















240 mg daily x 3 monthly 26.5 9.2, 75.7 93.3 66.8 42.8 58.3 408.2 185.9, 897.2
240 mg x 1 weekly 55.2 20.6, 147.2 99.7 95.3 83.7 NA 303.7 120.0, 722.3
320 mg daily x 3 monthly 35.3 12.2, 108.9 97.1 80.7 60.2 76.3 544.3 247.9, 1196.4
320 mg daily x 2 monthly 23.3 8.0, 66.6 89.5 59.2 36.4 45.3 441.5 173.7, 1007.9
320 mg x 1 twice monthly 29.1 10.1, 85.4 95.1 72.7 48.2 NA 334.7 124.6, 860.8
320 mg x 1 weekly 73.6 27.5, 196.2 100 98.1 93.5 NA 404.9 172.1, 963.1
400 mg daily x 3 monthly 44.2 15.3, 126.1 98.8 87.8 72.1 86.8 680.1 309.8, 1495.5
400 mg daily x 2 monthly 29.1 10.0, 83.2 95.1 71.2 48.9 60.6 551.9 217.1, 1259.8
400 mg x 1 twice monthly 36.3 12.6,106.7 97.8 82.9 62.4 41.6 418.4 155.8, 1076
400 mg x 1 weekly 92.0 34.3, 245.2 100 99.3 96.4 NA 506.1 215.0, 1203.9
*Day 30 except for weekly administration, in which case it is day 28
NA = not applicable
doi:10.1371/journal.pone.0154623.t002
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Effects of loading dose on piperquine exposure
Simulations revealed that PQ capillary plasma concentrations with repeated dosing are
expected to reach steady-state in approximately three months (Figs 1 and 2). The PQ steady-
state concentrations after multiple treatments relative to with a single treatment are approxi-
mately doubled due to accumulation. For example, after 3 consecutive daily doses of 240 mg,
the average (geometric mean) predicted PQ trough capillary plasma concentration at the end
of the first month is 13.2 ng/mL (95% prediction interval 5.1, 34.1 ng/mL), compared to
steady-state trough levels of 26.5 ng/mL (95% prediction interval 9.2, 75.7 ng/mL) if this dose
is given monthly. To address the reduced exposure in early months, we simulated the impact of
a loading dose (three consecutive daily doses at the beginning of the first dosing month), fol-
lowed by weekly dosing (Fig 2 and Table 3). The use of a 320 mg daily x 3 loading dose, fol-
lowed by 240 mg weekly dosing, is predicted to increase trough levels to 55.2 ng/mL at the end
of the first month (approximately the same value as the trough at steady-state), as compared to
41.2 ng/mL without a loading dose. Similarly, the use of this loading dose followed by a 320 mg
Fig 2. Predicted capillary plasma PQ concentration versus time for different doses of weekly chemoprevention
regimens of DP without and with a loading dose in 1–2 year olds weighing 11 kg. For each combination of dose
(240 mg, 320 mg, or 400 mg given weekly) and presence or absence of a loading dose, there is a set of 3 panels, with the
left panel (box plots) showing trough concentrations of the first 5 months, the middle panel the PK profile during the first
three days after the first dose, and the right panel the PK profile during days 3–28 relative to the first dose. For the PK
profiles, the middle line represents the population predictions, the grey shaded area the 50% prediction interval and the
outer bounds the 90% prediction interval. The grey horizontal lines indicate capillary plasma concentrations of 10, 20, and
30 ng/mL (for putative trough targets), and a capillary plasma level of 57 ng/mL (for a putative day 7 target).
doi:10.1371/journal.pone.0154623.g002
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weekly dose led to an 32% increase in the first-month trough level as compared to using the
320 mg weekly dose without a loading dose.
Discussion
A growing body of evidence supports the efficacy of monthly chemoprevention with DP in var-
ious epidemiologic settings [10–13, 18, 28]. While such an approach has been quite effective in
tightly controlled research studies, challenges with adherence to monthly regimens, the emer-
gence of resistance to DP in Southeast Asia, and concerns over the risk of cardiotoxicity with
repeated monthly treatment doses [20] warrant characterization of the profile of DP with alter-
native chemoprevention regimens. The objective of this PK simulation study was to apply pop-
ulation PK model-derived information to predict exposure with alternative DP
chemoprevention dosing regimens in young children. As precise PQ target levels for DP che-
moprevention remain unclear, we simulated steady-state troughs (end of the month), day 7
concentrations (which are associated with the risk of recurrent infection after treatment), and
peak concentrations (which may be predictive of toxicity) under differing dosing scenarios.
Our results suggest that weekly single dose DP will lead to higher steady-state trough PQ con-
centrations, as well as the proportion of individuals reaching specified trough levels, while at
the same time lowering the peak concentrations. Furthermore, the use of a loading dose is pre-
dicted to attain concentrations in the first several months following initiation of chemopreven-
tion that are more in line with those seen at steady-state.
Amongst our initial simulations was a comparison of previous mg/kg DP dosing regimens to
the newly revised increased 2015WHO regimen, as all published chemoprevention studies have
been performed under earlier mg/kg dosing regimens (Table 1) [1, 22]. Relative to the former
240 mg dose (daily x 3 given monthly), the revised 320 mg per dose regimen in young children
is predicted to provide a 38% increase in steady-state troughs with 60% of children maintaining
capillary troughs above 30 ng/mL, as compared to 43% under prior dosing weight bands. These
results are consistent with a recent simulation study utilizing the Thai adult chemoprevention
data which found that the newly revised WHO dosing regimen provides a significant improve-
ment in efficacy in all weight groups, but particularly in those weighing 8 to 12 kg [18, 29].
While it is anticipated that current increased DP mg/kg dosing guidelines will improve PK
exposure in both treatment and chemopreventiion settings, adherence to the regimen for the
latter, with three consecutive daily doses each month, is likely to be challenging [13, 30]. A
recent study in a high transmission region of Uganda found that while DP was the most effica-
cious of chemopreventive regimens studied, it was still only 58% effective with 52% of children
Table 3. Comparative predicted capillary plasma PQ concentrations with and without a loading dose of DP and predictedmaximum concentration





Predicted Ratio of Day 7
Concentration after First Dose to
Day 7 Concentration at Steady-
State




















0.75 (0.20, 2.85) 1.01 (0.27,
3.80)







0.21 (0.06, 0.79) 0.75 (0.20,
2.85)
0.50 (0.13, 1.86) 0.66 (0.17,
2.49)
494.3 200.6, 1116.3
400 mg weekly 320 mg daily
x 3
0.21 (0.06, 0.79) 0.75 (0.20,
2.85)
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having undetectable PQ at the time of diagnosis, suggesting a lack of adherence [13]. It is possi-
ble that the provision of single doses at a regular interval (particularly weekly) may improve
adherence over a regimen that is administered for three consecutive days of each month,
though this remains to be evaluated in field settings. Our simulated regimens thus included sin-
gle dose twice monthly and weekly administration which may provide simplified dosing at reg-
ular intervals. Most promising was the provision of weekly chemoprevention, with an
associated 2- to 3.5-fold increase in steady-state trough concentrations compared to monthly
dosing. Notably, mean steady-state trough concentrations with all weekly doses are predicted
to be higher than the protective venous trough level of 20 ng/mL reported recently (which is
predicted to correspond to a capillary level of approximately 50 ng/mL) [17, 29]. Splitting a
total dose into two or more fractional doses (and giving more frequently) has the additional
benefit that if a dose is missed, it does not have as much impact on the average systemic expo-
sure [31]. If the same (or even greater) percentage of pills are missed overall relative to monthly
dosing, dividing a similar total monthly dose into multiple doses throughout the month is still
likely to result in higher PQ trough concentrations. In a trial comparing once daily to twice
daily antiretroviral therapy, the probability of sustained virologic response was higher (89%
versus 76%) with the latter, despite less adherence (80% versus 91%) because trough levels of
the antiretroviral lopinovir were higher [32].
Another potential weakness of current chemopreventive approaches is the time that is
required to reach steady-state. With the provision of three consecutive daily doses, steady-state
is projected to be achieved after a few months of dosing, placing individuals at a higher risk of
breakthrough infections in the first few months after initiation. In the recent Thai adult study,
4 of 5 new infections occurred during the first 2 months of the trial before steady-state was
achieved [18]. Additionally, 32 of the 40 infections during the every-2-month DP arm occurred
in the second month after a dose, also supporting the notion that target concentrations need to
be maintained for the duration of the dosing interval for optimal efficacy. To address this con-
cern, we simulated the use of a loading dose (the standard three consecutive daily dose regi-
men), followed by a repeated weekly single 320 mg dose regimen (Table 3, Fig 2). The use of a
loading dose is predicted to increase PQ exposure closer to steady-state in the first few months,
as compared to weekly dosing without the loading dose. Levels of PQ on day 7 of the 1st month
are expected to be 75% of steady-state with the use of a loading dose as compared to 21% of
steady-state without a loading dose. Improved exposure in the first two months of chemopre-
vention is particularly critical in high transmission settings and in the setting of SMC, where
DP is only administered for a few months of the year.
An obvious concern with certain alternative regimens is that of potentially greater toxicity,
the most serious of which is corrected QT (QTc) interval prolongation [33]. Most notably, a
recent trial was halted due to concerns of QT prolongation when a compressed monthly 2-day
treatment was attempted in healthy adults, and that toxicity was felt to relate to PQ peak con-
centrations [20]. Importantly, our simulations suggest that weekly dosing decreases predicted
peak levels, despite higher steady-state trough concentrations (Tables 2 and 3). In other words,
our simulations suggest that both improved efficacy and lower risks of toxicity may be achieved
with this approach.
An additional concern that one must consider with repeated dosing in chemoprevention is
the potential for the emergence and selection of resistance [34]. Resistance to both artemisinins
and PQ has been described in Asia, and the potential emergence or spread of resistance in
Africa is of great concern [3–5, 35–37]. While we did not model PK-resistance relationships in
this study, regimens that provide higher steady-state troughs are those with shorter dosing
intervals, resulting in concentrations that are more likely to be above a “protective” threshold
where the development or selection for resistance may occur. Further, the use of twice monthly
Simulations of Piperaquine Chemoprevention Dosing Regimens
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or weekly doses may be associated with “insufficient” exposure to PQ after the first dose(s), as
compared with levels after a standard “treatment” dose, thereby placing one at risk for selection
or emergence of resistant PQ parasites. The use of a “loading dose” at the start of chemopre-
vention improves the likelihood of parasite eradication in asymptomatically-infected individu-
als, thereby reducing this potential risk.
An additional challenge in our PK simulation study was to define a target “protective” PQ
concentration, as a clear target has not been described for chemoprevention. While data are
emerging [18, 29], multiple factors such as transmission intensity, presence of artemisinin or
partner drug resistance, immunity of the population, age (adults vs children), and pregnancy
status are likely to impact protective thresholds. In the absence of such PK/PD data, we chose
to evaluate several PQ targets at troughs and at day 7 to allow for comparatives PK exposure
profiles among dosing approaches. In the future, a fully systematic approach would be ideal,
combining known PK models with mechanistic disease and drug-disease (i.e., PD) models to
predict response under appropriate conditions and assumptions. Such mechanistic models for
malaria and its treatment are being developed [29, 38–44].
A limitation of the current study is our focus on the long-acting partner drug PQ, without
simulating exposure to the short-acting artemisinin, DHA. Most notably, the PD impact of
altered DHA exposure under modified dosing regimens (bimonthly, weekly) is an important
consideration. Currently, no PK data for artemisinins is available from chemoprevention stud-
ies, though a recent study has modeled DHA exposure and parasite killing rates under differing
DP treatment regimens [45]. In addition, our study uses PK information from a diseased popu-
lation to make predictions in a non-diseased population. While alterations in PK in the pres-
ence of malaria have been identified for some antimalarials, namely lumefantrine, [46]
artusenate, [47–49] and halofantrine, [48], such data for PQ are limited, though some alter-
ation in PK almost certainly is to be expected. Of note, a significant effect of baseline parasite
density on drug clearance or relative bioavailability was not detected in the PQ data from
which our model was derived [6].
In summary, we believe that this or similar simulation approaches can be very beneficial in
choosing dosing strategies for chemoprevention trials of DP and other antimalarial regimens.
Our simulations predict that, in young children receiving a weekly single dose of DP, excellent
exposure can be maintained throughout the dosing interval while lowering peak PQ concentra-
tions, compared to current monthly “treatment” doses. Weekly dosing is also expected to main-
tain higher troughs when adherence is imperfect. The use of a loading dose may further
enhance the potential for success through the “complete” eradication of parasites and reduction
in breakthrough infections during the first month. It is critical that the impact of the predicted
exposure (average, trough and peak) be considered in the context of patient- and regional-spe-
cific requirements for efficacy, toxicity, ease of administration, adherence, and risk of resistance.
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